Rallybio Corporation (RLYB)
Largest Insider Buys in Sector
RLYB Stock Price History Chart
RLYB Stock Performance
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a …
Insider Activity of Rallybio Corporation
Over the last 12 months, insiders at Rallybio Corporation have bought $0 and sold $0 worth of Rallybio Corporation stock.
On average, over the past 5 years, insiders at Rallybio Corporation have bought $13.11M and sold $5.24M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $26,050 was made by Lieber Jonathan I () on 2023‑03‑14.
List of Insider Buy and Sell Transactions, Rallybio Corporation
| 2023-03-14 | 5,000 0.0123% | $5.21 | $26,050 | -13.69% | ||||
| 2023-03-07 | Sale | director | 100,000 0.242% | $8.20 | $820,000 | -44.54% | ||
| 2023-03-07 | Sale | 10 percent owner | 100,000 0.242% | $8.20 | $820,000 | -44.54% | ||
| 2022-06-03 | Sale | 99,671 0.4398% | $12.50 | $1.25M | -23.70% | |||
| 2022-06-03 | Sale | 99,671 0.4398% | $12.50 | $1.25M | -23.70% | |||
| 2022-05-23 | Sale | 33,553 0.1126% | $13.00 | $436,189 | -43.36% | |||
| 2022-05-23 | Sale | 33,553 0.1126% | $13.00 | $436,189 | -43.36% | |||
| 2022-03-21 | See Remarks | 3,000 0.0103% | $8.04 | $24,120 | +4.79% | |||
| 2022-02-08 | Sale | director | 210,000 0.6366% | $13.05 | $2.74M | -36.62% | ||
| 2022-02-08 | Sale | 10 percent owner | 210,000 0.6366% | $13.05 | $2.74M | -36.62% | ||
| 2022-01-19 | See Remarks | 1,400 0.0046% | $8.70 | $12,180 | +7.49% | |||
| 2022-01-13 | See Remarks | 5,000 0.0172% | $9.15 | $45,752 | +6.63% | |||
| 2022-01-12 | See Remarks | 5,000 0.0176% | $10.55 | $52,750 | -5.66% | |||
| 2022-01-11 | Chief Executive Officer | 4,496 0.0146% | $10.65 | $47,882 | -13.16% | |||
| 2022-01-10 | Chief Executive Officer | 5,504 0.0172% | $10.10 | $55,590 | -11.65% | |||
| 2022-01-07 | See Remarks | 10,000 0.0313% | $9.41 | $94,069 | -4.69% | |||
| 2021-08-02 | director | 76,923 0.2018% | $13.00 | $999,999 | -39.61% | |||
| 2021-08-02 | director | 307,692 0.8073% | $13.00 | $4M | -39.61% | |||
| 2021-08-02 | director | 576,923 1.5136% | $13.00 | $7.5M | -39.61% | |||
| 2021-08-02 | director | 615,384 1.6145% | $13.00 | $8M | -39.61% |
Insider Historical Profitability
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 4194777 10.1109% | $0.91 | 1 | 0 | <0.0001% |
| SHANNON TIMOTHY M | director | 2409712 5.8083% | $0.91 | 1 | 0 | <0.0001% |
| PARMAR KUSH | director | 2378969 5.7342% | $0.91 | 1 | 4 | <0.0001% |
| HUNT RONALD | director | 2301603 5.5477% | $0.91 | 1 | 0 | <0.0001% |
| Hopfner Robert Lorne | director | 2267411 5.4653% | $0.91 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Viking Global Investors | $7.76M | 10.12 | 4.19M | 0% | +$0 | <0.01 | |
| 5Am Venture Management Llc | $6.72M | 8.76 | 3.63M | 0% | +$0 | 0.45 | |
| New Leaf Venture Partners | $6.11M | 7.97 | 3.3M | 0% | +$0 | 5.82 | |
| Tpg Gp A Llc | $5.6M | 7.31 | 3.03M | 0% | +$0 | 0.11 | |
| Pivotal Bioventure Partners Investment Advisor Llc | $4.45M | 5.8 | 2.4M | 0% | +$0 | 3.58 |